Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials-Reference-Cited by-同舟云学术

Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials

Published:2005-05 Issue: Volume:16 Page:iv123-iv131
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Gebbia V.,Galetta D.,De Marinis F.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/16/suppl_4/iv123/385804/mdi921.pdf

Reference70 articles.

1. Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Who, What, When, Why;Bunn;J Clin Oncol,2002

2. Management of Advanced Non–Small-Cell Lung Cancer in Patients with a Performance Status of 2;Lilenbaum;Clin Lung Cancer,2004

3. Prognostic factor for survival in patients with inoperable lung cancer;Stanley;J Natl Cancer Inst,1980

4. Prognostic factors in advanced non-small-cell lung cancer: analysis of Eastern Cooperative Oncology Group trials from 1981–1992;Jiroutek;Proc Am Soc Clin Oncol,1988

5. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience;Albain;J Clin Oncol,1991

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17;European Journal of Cancer;2024-03

2. Recent Developments and Challenges in Molecular-Targeted Therapy of Non-Small-Cell Lung Cancer;Journal of Environmental Pathology, Toxicology and Oncology;2023

3. Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts;Cancers;2022-12-13

4. Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy;Future Oncology;2022-07

5. Five-year results of nivolumab for the treatment of non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center;Meditsinskiy sovet = Medical Council;2021-08-07